Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need


19th Annual Needham Healthcare Conference
 April 15, 2020
 3:30pm - 4:30pm EDT

Dr. Thomas Adams, Chief Executive Officer and Chairman, and Dr. Mark Erlander, Chief Scientific Officer, of Trovagene, will provide an overview of the Company's business and advancing clinical development programs for its investigational drug, onvansertib, during the live presentation. They will also be conducting one-on-one calls with investors throughout the conference.

The company presentation will take place at 3:30 pm EDT on Wednesday, April 15th, 2020.  A webcast of the presentation will be availalbe on the Trovagene website for 90 days.